TrivarX Expands into Brain Cancer Imaging as Veteran Trial Validates Depression Diagnostic

TrivarX Limited ( (AU:TRI) ) has shared an announcement.

TrivarX has exercised its option to acquire 100% of the Stabl-Im brain imaging intellectual property from Nucleics Pty Ltd, expanding its portfolio beyond ECG-based diagnostics into neuro-oncology. Stabl-Im is designed to use stable isotope labelling with standard MRI to detect active tumour growth earlier and more safely than conventional imaging, potentially enabling non-invasive monitoring of brain cancers and brain metastases in a global neuro-oncology market valued at hundreds of millions of dollars, with related treatment markets projected in the billions. Alongside this strategic move, the company reported clinically meaningful results from a US Veterans Affairs-backed trial using its single-lead ECG algorithm to screen for current major depressive episodes in veterans with suspected sleep apnoea, demonstrating sensitivity and specificity broadly comparable to its more complex multi-biomarker MEB-001 algorithm. Together with a recently completed A$4.2 million placement to fund development and near-term plans for regulatory engagement and Phase 1 trials, these developments support TrivarX’s bid to strengthen its position in neurological and mental health diagnostics and open new partnering and commercialisation avenues.

The most recent analyst rating on (AU:TRI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on TrivarX Limited stock, see the AU:TRI Stock Forecast page.

More about TrivarX Limited

TrivarX Limited is an ASX-listed medical technology company focused on data-driven diagnostics in mental health, sleep health and neurology. Historically centred on ECG-based diagnostic algorithms, the company is now broadening into neuro-oncology imaging through the acquisition and development of Stabl-Im, a stable-isotope-based brain cancer imaging platform targeting large, high-value global diagnostic and treatment markets.

YTD Price Performance: 5.26%

Average Trading Volume: 1,348,697

Technical Sentiment Signal: Sell

Current Market Cap: A$23.07M

For an in-depth examination of TRI stock, go to TipRanks’ Overview page.